Stock A047920 HLB PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

HLB Pharmaceutical Co., Ltd. Share Price

Equities

A047920

KR7047920004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
34,900 KRW +0.72% Intraday chart for HLB Pharmaceutical Co., Ltd. +10.27% +129.45%
2023 HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors CI
2023 HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors CI

Financials

Sales 2018 20.54B 14.93M 1.2B Sales 2019 36.1B 26.24M 2.1B Capitalization 75.19B 54.67M 4.38B
Net income 2018 -7.06B -5.13M -411M Net income 2019 473M 344K 27.54M EV / Sales 2018 2.78 x
Net cash position 2018 1.41B 1.03M 82.28M Net cash position 2019 1.96B 1.43M 114M EV / Sales 2019 2.03 x
P/E ratio 2018
-8.1 x
P/E ratio 2019
159 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 81.48%
More Fundamentals * Assessed data

Chart HLB Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about HLB Pharmaceutical Co., Ltd.

HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd. CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd. CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 12.138369345 billion in funding from HLB Pharmaceutical Co., Ltd CI
G-treeBNT Co., Ltd. announced that it has received KRW 95.000054256 billion in funding from a group of investors CI
HLB Pharmaceutical Co., Ltd(KOSDAQ:A047920) added to S&P Global BMI Index CI
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 95.000054256 billion in funding from a group of investors CI
Verismo Therapeutics, Inc. announced that it has received KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in funding CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in funding CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from EBEST Investment & Securities Co., Ltd. CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from HLB Co., Ltd. and other investor. CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd. CI
More news

Quotes and Performance

1 day+0.72%
1 week+10.27%
Current month-5.16%
1 month-6.06%
3 months+130.97%
6 months+190.11%
Current year+129.45%
More quotes

Highs and lows

1 week
31 450.00
Extreme 31450
36 500.00
1 month
27 700.00
Extreme 27700
40 300.00
Current year
12 880.00
Extreme 12880
42 050.00
1 year
11 780.00
Extreme 11780
42 050.00
3 years
7 860.00
Extreme 7860
42 050.00
5 years
2 665.00
Extreme 2665
42 050.00
10 years
2 665.00
Extreme 2665
42 050.00
More quotes

Managers and Directors - HLB Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Jae-Hyeong Park CEO
 Chief Executive Officer 58 15/10/20
Bok-Hwan Jeon CEO
 Chief Executive Officer 60 15/10/20
Kang-Beom Kwon AUD
 Comptroller/Controller/Auditor 54 -
Members of the board TitleAgeSince
Tae-Hyeon Park BRD
 Director/Board Member 66 -
Jae-Hyeong Park CEO
 Chief Executive Officer 58 15/10/20
Bok-Hwan Jeon CEO
 Chief Executive Officer 60 15/10/20
More insiders

Quotes

Date Price Change Volume
26/04/24 34,900 +0.72% 1,058,979
25/04/24 34,650 -0.29% 718,026
24/04/24 34,750 +0.58% 586,515
23/04/24 34,550 +0.14% 642,043
22/04/24 34,500 +9.00% 2,297,734

End-of-day quote Korea S.E., April 25, 2024

More quotes

Company Profile

HLB Pharmaceutical Co Ltd, formerly Mediforum Pharmaceutical Inc, is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets and other ethical the counter (ETC) drugs; gynobetadine vaginal suppositories, and other over the counter (OTC) drugs; aceclofenac tablets, revotec tablets and other commissioned ETC drugs; L-carnitine tablets, elcatan tablets, hepatine liquids and other commissioned OTC drugs.
Sector
Pharmaceuticals
Calendar
09/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
HLB PHARMACEUTICAL CO., LTD. Stock HLB Pharmaceutical Co., Ltd.
+129.45% 356M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A047920 Stock